Should we treat Gleason 6 prostate cancer? M. Wirth, Dresden (DE)
Data on phase III pivotal trials of TOOKAD® Soluble vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer M. Emberton, London (GB)
How will focal therapy change current treatment of localized prostate cancer N. Mottet, Saint-Étienne (FR)
Technical aspect of VTP Surgery A.R. Azzouzi, Angers (FR)
Introduction into the mechanism of action of vascular-targeted photodynamic therapy - TOOKAD® Soluble A. Scherz, Rehovot (IL)